Featured Studies Results

A Study of the Drug REC-4881 For Treating People with Advanced Cancers with an APC or AXIN1 Mutation identifier:
NCT06005974 (

Treatment study for people with advanced cancer with an APC or AXIN1 mutation

FORCE Survey for People at Increased Risk for Breast or Gynecologic Cancer Due to an Inherited Mutation

Surveys, Registries, Interviews
Survey for people at high risk for breast and gynecologic cancer due to an inherited mutation

Testing the Safety And Action of the Investigational Drug REC-4881 in People With Familial Adenomatous Polyposis (FAP) (TUPELO Study) identifier:
NCT05552755 (

Prevention study for people with an APC mutation and FAP who have had colectomy surgery

Studies for People with ER-Positive, HER2-Negative Advanced or Metastatic Breast Cancer (TACTIVE-U)

Treatment for ER-positive, HER2-negative metastatic breast cancer

Studies for People With ER-Positive, HER2-Negative Advanced or Metastatic Breast Cancer (VERITAC Studies)

Treatment studies for ER-positive, HER2-negative metastatic breast cancer

Pancreatic Cancer Early Detection for People at High Risk identifier:
NCT04970056 (

Registry and biobank for high risk people undergoing pancreatic cancer screening

Cancer Prevention Vaccine (Nous-209) for People with Lynch Syndrome identifier:
NCT05078866 (

Prevention study for people with Lynch syndrome

Lynch Syndrome Vaccine Study identifier:
NCT05419011 (

Testing A Combination Of Vaccines For Cancer Prevention In Lynch Syndrome

A Study to Compare Two Surgical Procedures in Women with BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer (SOROCk) identifier:
NCT04251052 (

Ovarian cancer prevention for women with a BRCA1 mutation who still have their ovaries

Study of a New Immunotherapy Treatment Called NC410 in People with Different Types of Advanced or Metastatic Cancers identifier:
NCT05572684 (

People with advanced or metastatic colorectal, endometrial, ovarian, stomach, esophageal or other cancers

PROMISE Registry: A Prostate Cancer Registry of Outcomes and Germline Mutations for Improved Survival and Treatment Effectiveness identifier:
NCT04995198 (

Surveys, Registries, Interviews
A screening registry for people diagnosed with prostate cancer

Combining the Immunotherapy Dostarlimab and PARP Inhibitor Niraparib for Advanced or Metastatic Breast, Ovarian or Pancreatic Cancer with an Inherited or Tumor BRCA Mutation identifier:
NCT04673448 (

Treatment study for people with advanced breast, ovarian or pancreatic cancer and an inherited or tumor BRCA mutation

Studying a Combination of Three Drugs to Treat Previously Untreated Metastatic Colorectal Cancer which Is MSI-High and Has a BRAF V600E Mutation identifier:
NCT05217446 (

Study for metastatic colorectal cancer that has not yet been treated

Using ctDNA Blood Test for Earlier Detection and Treatment of Recurrence or Spread after Treatment for Stage 3 Colon Cancer identifier:
NCT03803553 (

Monitoring and treatment study for people who completed treatment for stage 3 colon cancer

TAPUR Study: Testing FDA Approved Drugs Targeting Tumor Biomarkers in People with Advanced Stage Cancer identifier:
NCT02693535 (

Cancer treatment study for people with advanced solid tumors

Exploring How People of Caribbean Descent Share Information About Their Genetic Mutations with Family Members

Surveys, Registries, Interviews
Survey and interview for people of Caribbean descent who tested positive for a genetic mutation linked to cancer.

Testing a Vaccine for Treating or Preventing Triple-Negative Breast Cancer identifier:
NCT04674306 (

Treatment study for people with stage 2 or 3 triple-negative breast cancer at high risk for recurrence.

Comparing a Combination of Drugs for Treatment of HER2-positive Colorectal Cancer as First Line Treatment in the Metastatic Setting identifier:
NCT05253651 (

People with HER2-positive colorectal cancer who have not yet received treatment in the metastatic setting

Preferences Survey for Women With an Inherited BRCA Mutation and Without a Cancer Diagnosis

Surveys, Registries, Interviews
Online survey for women with a BRCA1 or BRCA2 inherited mutation and no personal history of cancer.

Coaching for Family Caregivers of People with Advanced Cancer from Rural and Minority Communities identifier:
NCT04318886 (

Quality of Life
Quality of life study for caregivers involving in-person or telephone coaching sessions

Study of Colorectal Cancer and Genetics in Hispanic and Latino People (ENLACE Study)

Hispanic and Latino people diagnosed with colorectal cancer

Testing a Vaccine for Preventing or Treating Triple-Negative Breast Cancer identifier:
NCT04674306 (

Prevention study for people with a BRCA1, BRCA2 or PALB2 inherited mutation who are planning to undergo risk-reducing mastectomy.

Men at High Genetic Risk for Prostate Cancer identifier:
NCT03805919 (

Prostate screening with MRI for men with Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM) or a BRCA1, BRCA2, HOXB13, ATM, NBN, TP53, BRIP1, CHEK2, PALB2, RAD51C, RAD51D, or other mutation

Collecting Blood and Stool Samples to Detect Colorectal Cancer or Precancerous Polyps in Lynch Syndrome Patients, CORAL Study identifier:
NCT05410977 (

People with Lynch Syndrome at risk for colon cancer

Study of the PARP inhibitor AZD9574 Alone and Combined with Other Cancer Medicines to Treat People with Advanced Solid Cancers (CERTIS1 Study) identifier:
NCT05417594 (

Treatment study for people with advanced breast, ovarian, pancreatic or prostate cancer or gliomas

The WISDOM Study: Women Informed to Screen Depending on Measures of Risk identifier:
NCT02620852 (

Study to Determine if Breast Cancer Screening can be Made Better by Personalizing Each Woman’s Mammogram Schedule

LIVING WELL: A Web-Based Program to Improve Quality of Life in Ovarian Cancer Survivors identifier:
NCT04533763 (

Quality of Life
A research program offering mindfulness, coping, and healthy lifestyle skills for ovarian cancer survivors.

MRI Screening in Men at High Risk of Developing Prostate Cancer identifier:
NCT05608694 (

Screening using MRI for men at risk of developing prostate cancer

My Best GI Eating Study identifier:
NCT05396846 (

Diet and weight loss study for people who are overweight and at increased risk of colorectal cancer

Helping Latinas Understand Their Risk for Breast Cancer and Get Breast Cancer Care identifier:
NCT05483283 (

Latinas with a high risk of breast cancer

Intimacy and Self-Esteem Among Sexual and Gender Minority Cancer Survivors (RISE-SGM)

Surveys, Registries, Interviews
A one-time interview study to explore experiences with sexual functioning, sexual relationships, sexual self-concept, and self-esteem of 18-39-year-old sexual and/or gender minority cancer survivors

Studying People and Families Affected by Li-Fraumeni Syndrome (TP53 Mutation ) identifier:
NCT01443468 (

Surveys, Registries, Interviews
Registry for people with Li-Fraumeni syndrome (LFS) or from LFS families

Registry to Promote Health Equity for People of African Ancestry with Breast or Prostate Cancer identifier:
NCT05754658 (

Surveys, Registries, Interviews
This is a registry for people of African ancestry who have breast or prostate cancer

A Surveillance Program for Women at High Risk for Breast Cancer (CAPSBRACA) identifier:
NCT03729115 (

Surveys, Registries, Interviews
Screening study for women at risk for breast cancer due to an inherited mutation or other risk factor

Survey For Individuals With A Hereditary Cancer Genetic Testing Result That Was Later Reclassified

Survey for people whose genetic test results were reclassified

Testing the Drug Obeticholic Acid for Familial Adenomatous Polyposis identifier:
NCT05223036 (

Prevention study for people with an APC mutation and FAP or AFAP who have polyps in remaining tissue after colectomy surgery

A Randomized Study of Robotic-Assisted Nipple Sparing Mastectomy vs. Standard Surgery Nipple Sparing Mastectomy for Early Stage Breast Cancer identifier:
NCT05720039 (

Nipple sparing mastectomy with reconstruction for women with early-stage breast cancer

Testing a Vaccine for Cancer Prevention in People with a BRCA1 or BRCA2 Mutation identifier:
NCT04367675 (

People with a BRCA1 or BRCA2 mutation

Denosumab for Breast Cancer Risk Reduction in Women With an Inherited BRCA1 Mutation (The Breast Cancer Prevention Study) identifier:
NCT04711109 (

Prevention study enrolling women ages 25-55 with a BRCA1 mutation

Survey about Motivations and Barriers to Talking with Family Members about Inherited Cancer Risk

Surveys, Registries, Interviews
Survey for people with an inherited gene mutation

A Study of Targeted Therapies for Patients With Recurrent Endometrial Cancer identifier:
NCT04486352 (

This study is to test the safety and effectiveness of different kinds of targeted therapy with or without atezolizumab (or Tecentriq) in individuals with recurrent endometrial cancer.

A Study Comparing Two Anti-inflammatory Medications Naproxen or Aspirin for Cancer Prevention in Lynch Syndrome identifier:
NCT05411718 (

Prevention study for people with Lynch syndrome

Kindred Study

Surveys, Registries, Interviews
Interviews with African American people who tested positive for a genetic mutation

Testing an Immunotherapy, Pembrolizumab, in Patients With Advanced Solid Tumors identifier:
NCT02628067 (

Treatment study for people with advanced cancers

Upright MRI for Prostate Cancer Screening identifier:
NCT03474913 (

Screening for prostate cancer using upright MRI

Comparing Three Drugs as Late-Stage Treatment for Individuals with Metastatic Colorectal Cancer identifier:
NCT05328908 (

treatment study for people with metastatic colorectal cancer

Self -Perception and Intimacy After the Cancer Experience (SPICE)

Surveys, Registries, Interviews
Online survey for cancer survivors ages 18-39 years old about sexual health

Metastatic Castration Resistant Prostate Cancer Clinical Trial identifier:
NCT03460977 (

This clinical trial is studying a potential treatment for men with metastatic castration resistant prostate cancer.

Investigating the Use of Self-Acupressure for Fatigue in Ovarian Cancer Survivors identifier:
NCT03763838 (

Quality of Life
University of Michigan researchers are investigating the use of self-acupressure for fatigue in ovarian cancer survivors.

Survey for Women at High Risk for Breast Cancer on Knowledge and Perspectives about Breast Cancer Risk Factors and Screening

Surveys, Registries, Interviews
Online survey for women with an ATM, BARD1, BRCA1, BRCA2, CDH1, CHEK2, PALB2, PTEN, RAD51C, RAD51D, STK11 or TP53 inherited mutation.

Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects identifier:
NCT04030559 (

High-risk localized prostate cancer

Testing Immunotherapy Treatments for Recurrent Endometrial Cancer identifier:
NCT05112601 (

Treatment study for people with endometrial cancer that has returned

Opening the Conversation identifier:
NCT04806724 (

Quality of Life
Online communication program for breast and gynecologic cancer survivors and their partners

Treating Metastatic Solid Tumors with an Inherited or Acquired Gene Mutation Using the PARP Inhibitor Talazoparib identifier:
NCT04550494 (

Treatment study for people with advanced solid tumors

Combined Pembrolizumab & Quavonlimab (MK-1308A) Versus Other Treatments in People With MSI-High or dMMR Stage IV Colorectal Cancer identifier:
NCT04895722 (

Stage 4 colorectal cancer

Survey for People Diagnosed with Breast Cancer to Provide Feedback on a New Type of Clinical Trial

Surveys, Registries, Interviews
Survey for people diagnosed with stage 0 - stage 3 breast cancer

Pancreatic Cancer Screening Study (CAPS5) identifier:
NCT02000089 (

Screening study for people at high risk for pancreatic cancer

Combination ATR inhibitor and PARP Inhibitor in Recurrent Ovarian Cancer (CAPRI) identifier:
NCT03462342 (

Recurrent ovarian cancer

Effect of Acupuncture on Memory and Thinking Difficulties after Breast Cancer identifier:
NCT04837820 (

Quality of Life
Acupuncture study for people with memory issues who completed treatment for stage 0-3 breast cancer

Restoring Sensation after DIEP Flap Reconstruction identifier:
NCT04533373 (

Study for people undergoing DIEP flap reconstruction

A Randomized Study of Olaparib or Placebo in Patients with Surgically Removed Pancreatic Cancer who have a BRCA1, BRCA2 or PALB2 Mutation (APOLLO) identifier:
NCT04858334 (


Effects of Occupational Therapy Telehealth Intervention on Cancer-Related Cognitive Impairment in Breast Cancer Survivors identifier:
NCT05505045 (

Quality of Life
Telehealth study for breast cancer survivors with memory issues

Tools To Be Fit: Tools to Improve Nutrition and Physical Activity for Cancer Survivors identifier:
NCT05056077 (

Quality of Life
Bladder, breast, colon, endometrial, kidney (renal cell carcinoma), ovarian, prostate, or rectal cancer

Factors Influencing Disparities in Quality of Life among People of Color Affected by Cancer

Surveys, Registries, Interviews
Survey for people of color who have completed treatment for cancer

Prostate Cancer Genetic Risk Evaluation and Screening Study (PROGRESS) identifier:
NCT05129605 (

People at high risk for prostate cancer due to an inherited mutation

NUV-868 Alone and in Combination With PARP Inhibitors in Patients With Advanced Solid Tumors identifier:
NCT05252390 (

Treatment study for people with advanced solid tumors, including triple-negative breast, ovarian, pancreatic and prostate cancer

Opening the Conversation Study identifier:
NCT04806724 (

Quality of Life
Videoconference sessions that address cancer related concerns for couples

Study of Physical Activity at Home for Relief from Neuropathy Caused by Taxanes in People with Breast Cancer identifier:
NCT04621721 (

Quality of Life
Quality of life study for breast cancer patients experiencing neuropathy from chemotherapy

Treating Metastatic Prostate Cancer with Chemotherapy or PARP Inhibitor in People with Mutations (COBRA) identifier:
NCT04038502 (

Treatment study for mCRPC with an inherited or tumor mutation in BARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2, RAD51B, RAD51C, RAD51D or RAD54L

Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women (TUBA/WISP II) identifier:
NCT05287451 (

Prevention study for women at high risk for ovarian cancer

Blood Markers of Early Pancreas Cancer identifier:
NCT03568630 (

Observational study for people with family history of pancreas cancer or an inherited mutation linked to pancreatic cancer risk.

Study of Oral Drug Bazedoxifene Plus Conjugated Estrogens for Treating Hot Flashes in Women at High Risk for Breast Cancer identifier:
NCT04821141 (

Quality of Life
Women at high risk for breast cancer due to ATM, CDH1, CHEK2, NBN, NF1, PALB2, PTEN, STK11, P53 or PTEN mutation who have hot flashes

Research Opportunity for Previvors and their Romantic Partners

Surveys, Registries, Interviews
Interview for people with inherited mutations who had risk-reducing mastectomy and their partners

Young, Empowered & Strong: Web-Based Symptom Monitoring and Self-Management for Young Adult Breast Cancer Survivors (YES Study) identifier:
NCT04906200 (

Quality of Life
Women diagnosed with breast cancer between the ages of 15-39

BRCA 1 and 2: Interviews on Genetic Testing and Individual Experiences

Surveys, Registries, Interviews
People with or without cancer who have had or are considering BRCA testing

Cancer Experience Registry

Surveys, Registries, Interviews
Online survey for patients and caregivers focusing on multiple aspects of cancer

SHARON: A Clinical Trial for Metastatic Cancer With an Inherited BRCA or PALB2 Mutation Using Chemotherapy and Patients’ Own Stem Cells identifier:
NCT04150042 (

Advanced pancreatic cancer or stage 4 breast cancer in people with a BRCA1 or BRCA2 mutation

Chemotherapy, Immunotherapy and PARP Inhibitor for the Treatment of Metastatic Aggressive Variant Prostate Cancer identifier:
NCT04592237 (

Treatment in people with aggressive metastatic prostate cancer

IGNITE-TX - Identifying Individuals for Genetic Testing for Familial Cancer identifier:
NCT05677048 (

People with a genetic mutation in BRCA1, BRCA2 or Lynch syndrome who have relatives who have not been tested

All of Us Research Program

Surveys, Registries, Interviews
Anyone age 18 or over

Treating Early-Stage HER2-Negative Breast Cancer with a PARP Inhibitor (Niraparib) and Immunotherapy (Dostarlimab) in People with a BRCA or PALB2 Mutation identifier:
NCT04584255 (

Treatment before surgery for people with early-stage breast cancer & a BRCA1, BRCA2 or PALB2 mutation

Androgen Suppression With Abiraterone, Leuprolide, PARP Inhibitor and Stereotactic Radiotherapy in Prostate Cancer (ASCLEPIuS) identifier:
NCT04194554 (

Newly diagnosed prostate cancer grade group 3-5

Investigational PARP Inhibitor AZD5305 Alone or Combined With Other Anti-cancer Agents in People With Advanced Solid Tumors (PETRA) identifier:
NCT04644068 (

Advanced ovarian, breast, prostate or pancreatic cancer

Inherited Cancer Registry (ICARE): Contribute to Research While Staying Informed identifier:
NCT03231891 (

Surveys, Registries, Interviews
People with an inherited mutation or cancer in the family

Adding Pembrolizumab to Olaparib to Treat Pancreatic Cancer in People with an Inherited BRCA Mutation identifier:
NCT04548752 (

Metastatic pancreatic cancer and a BRCA1 or BRCA2 mutation

Retifanlimab (Immunotherapy) Alone or Combined with Other Therapies for Advanced Endometrial Cancer that Progressed on or after Platinum Chemotherapy (POD1UM-204) identifier:
NCT04463771 (

Advanced endometrial cancer

Treatment with ATR Inhibitor for Advanced or Metastatic Solid Tumors identifier:
NCT04657068 (

Advanced solid tumors

Testing the New Targeted Therapy CYH33 in Combination With the PARP Inhibitor Olaparib in People With Advanced Solid Tumors and DNA Damage Repair Mutations identifier:
NCT04586335 (

Advanced solid tumors

Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient (dMMR/MSI-High) Cancers Resistant to Prior PD-L1 Inhibitor identifier:
NCT03607890 (

Solid tumors that are MSI-High and resistant to prior immunotherapy

Atorvastatin ± Aspirin for Colorectal Cancer Prevention for People with Lynch Syndrome identifier:
NCT04379999 (


Developing a Test for the Detection of Ovarian Cancer identifier:
NCT04794322 (


Chemotherapy, Bevacizumab, and/or Atezolizumab for Patients With Deficient DNA Mismatch Repair (dMMR or MSI-H) Metastatic Colorectal Cancer, the COMMIT Study identifier:
NCT02997228 (


Preliminary Evaluation of Screening for Pancreatic Cancer in Patients with an Inherited Genetic Risk Due to a BRCA1, BRCA2, PALB2 or ATM Mutation identifier:
NCT02478892 (


Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations identifier:
NCT04042831 (


Validating a Blood Test for Early Ovarian Cancer Detection in High-risk Women and Families: MicroRNA Detection Study (MiDE)

Screening study for women with a BRCA1, BRCA2, BRIP1, PALB2, RAD51C, RAD51D, PMS2, MLH1, MSH2, MSH6, or EPCAM mutation

A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC) (CheckMate 8HW) identifier:
NCT04008030 (

People with metastatic colorectal cancer that is MSI-High

Pembrolizumab and Olaparib for People With Metastatic Pancreatic Cancer with Homologous Recombination Deficiency or Exceptional Response to Platinum Chemotherapy identifier:
NCT04666740 (


A Survey on Options for Managing Cancer Risk Among Women with a BRCA1 or BRCA2 Mutation

Surveys, Registries, Interviews

Serum Biomarkers to Characterize the Effects of Therapy on Ovarian Reserve in Premenopausal Women With Early-stage Breast Cancer or BRCA Mutations identifier:
NCT00823654 (


A Phase 2 Study of Olaparib Monotherapy in Metastatic Breast Cancer Patients with Germline or Somatic Mutations in DNA Repair Genes (Olaparib Expanded) identifier:
NCT03344965 (


The Risk Factor Analysis of Hereditary Breast and Ovarian Cancer In Women with BRCA1, BRCA2 or PALB2 Mutations

Surveys, Registries, Interviews

Diagnosis of Breast Cancer in Young Women - Share Your Story

Surveys, Registries, Interviews

Talazoparib for People with Metastatic Breast Cancer Who Have Acquired (Somatic) BRCA Mutations identifier:
NCT03990896 (


A Randomized Study of an eHealth Delivery Alternative for Cancer Genetic Testing for Hereditary Predisposition in Metastatic Breast, Ovarian, Prostate and Pancreatic Cancer Patients identifier:
NCT04353973 (


Metastatic Prostate Cancer Project

Surveys, Registries, Interviews

The Metastatic Breast Cancer Project

Surveys, Registries, Interviews

A Pancreatic Cancer Screening Study for High Risk Individuals identifier:
NCT03250078 (


RANKL Inhibition With Denosumab on Mammographic Density in Premenopausal Women With Dense Breasts (TRIDENT) identifier:
NCT04067726 (


Connect My Variant

Surveys, Registries, Interviews

Genomic Services Research Program Study for People with Unexpected Genetic Results identifier:
NCT02595957 (


Talking to Employers and Medical Staff About Breast Cancer Treatment and Your Job (TEAMWork Study) identifier:
NCT03572374 (

Quality of Life

Breast Cancer Treatment in Women with PALB2 Mutations

Surveys, Registries, Interviews

Energetics and Lifestyle in Inherited Syndromes (ELLIE’s Study)

Quality of Life

Pragmatic Randomized Trial of Proton vs. Photon Therapy for Patients with Non-Metastatic Breast Cancer Receiving Comprehensive nodal Radiation: A Radiotherapy Comparative Effectiveness Trial identifier:
NCT02603341 (


Identification and Analysis of Families With Genetic Susceptibility To Cancer Registry

Surveys, Registries, Interviews

Pancreatic Cancer Early Detection Program identifier:
NCT02206360 (



FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.